 Well, we're going to continue talking about this after a break. And we're especially going to focus on some movement, I think, in the FDA and in looking at this in a different way. And I want both of you to weigh in on that. But we're going to first take a break. And we're talking about post-transplant drugs, what's holding up potential new medications. We're joined by Dr. Ken Newell. He's a transplant surgeon at Emory University Hospital.